STOCK TITAN

BioLineRX Ltd - BLRX STOCK NEWS

Welcome to our dedicated page for BioLineRX news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on BioLineRX stock.

BioLineRx Ltd. (NASDAQ: BLRX) is a commercial-stage biopharmaceutical company based in Modi'in, Israel, with operations extending to the United States. The company specializes in developing life-changing therapies for oncology and rare diseases. BioLineRx's flagship product, APHEXDA® (motixafortide), has gained approval in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma patients.

Currently, the company is advancing a robust pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors. One of their notable clinical-stage therapeutic candidates is motixafortide (BL-8040), a novel peptide showing promise in stem-cell mobilization and solid tumors. Another key candidate is AGI-134, an immuno-oncology agent dedicated to treating solid tumors.

BioLineRx recently announced definitive agreements with institutional investors for the issuance and sale of its American Depositary Shares (ADSs) and warrants. This equity transaction, combined with financial resources from an existing debt facility, positions the company well for the commercialization of APHEXDA and the advancement of its other pipeline programs. Additionally, the company is exploring motixafortide's potential in supporting gene therapy for sickle cell disease, collaborating with leaders in the gene therapy field such as St. Jude Children's Research Hospital and Washington University School of Medicine.

BioLineRx has also received recent notifications and presented new data at various esteemed conferences such as the American Society of Clinical Oncology (ASCO) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). These efforts underscore the company's commitment to bringing innovative therapies from the bench to the bedside.

To access more information about BioLineRx, visit their official website or follow them on Twitter and LinkedIn.

Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced significant findings related to motixafortide, a candidate for stem cell mobilization in multiple myeloma patients. The full pharmacoeconomic study shows cost benefits when using motixafortide with G-CSF compared to plerixafor with G-CSF, demonstrating reduced healthcare resource utilization and higher successful mobilization rates. Additionally, a Phase 1 trial design for using motixafortide in gene therapy for sickle cell disease will also be presented at the ASH Annual Meeting from December 10-13, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) has announced its plan for independent U.S. commercialization of APHEXDA (Motixafortide) for stem cell mobilization in multiple myeloma patients, contingent on FDA approval. Veteran product leader Holly May has been appointed as President, BioLineRx USA. The company aims to build a targeted sales force to engage with transplant centers, projecting a $360 million annual market opportunity. The recent NDA submission follows positive results from the GENESIS Phase 3 trial. A webinar is scheduled for September 28 to discuss the launch strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced a registered direct offering of 13,636,365 American Depositary Shares (ADSs) and warrants at a price of $1.10 per ADS, projected to raise gross proceeds of $15 million. The offering is expected to close around September 21, 2022. The funds will support the commercial launch of Motixafortide for multiple myeloma and other corporate needs, including clinical trials. The warrants have an exercise price of $1.15 per ADS and expire five years post-issuance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.77%
Tags
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced a $40 million non-dilutive debt financing agreement with Kreos Capital to support the U.S. commercial launch of Motixafortide. The initial $10 million tranche is available now, while the remaining $30 million will be released upon achieving specific milestones by October 2024. The financing will incur a fixed interest rate of 9.5% per annum, plus royalties on Motixafortide sales. The funds will be utilized for the aggressive launch of the drug for stem cell mobilization in multiple myeloma patients, pending FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced the submission of its New Drug Application (NDA) for Motixafortide to the FDA for stem cell mobilization in autologous bone marrow transplantation for multiple myeloma patients. This submission is based on positive results from the GENESIS Phase 3 trial, which met all endpoints with high statistical significance (p<0.0001). Approximately 90% of patients who received Motixafortide proceeded to transplantation after one administration, indicating significant clinical benefits. The FDA's review decision is expected in November 2022, with a potential PDUFA date in mid-2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.89%
Tags
none
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) has made significant advancements in its pipeline, with the submission of a New Drug Application (NDA) for Motixafortide in stem cell mobilization expected within 4-6 weeks. The company appointed Holly May as Chief Commercial Officer to enhance its commercial strategy. It also announced a collaboration with GenFleet Therapeutics for a Phase 2b trial in pancreatic cancer. As of June 30, 2022, BioLineRx reported $43.2 million in cash, sufficient to fund operations into H1 2024. The company experienced a net loss of $7.4 million for Q2 2022, up from $6.8 million in Q2 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) will release its unaudited financial results for Q2 2022 on August 16, 2022, before US market opens. Following this, a conference call will be held at 10:00 a.m. EDT, featuring remarks from CEO Philip Serlin. The call can be accessed via the company's Investor Relations page, with dial-in options available. BioLineRx focuses on oncology, with its lead program, Motixafortide, in various trials including one for pancreatic cancer. The company is also developing AGI-134, aimed at multiple solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
conferences
-
Rhea-AI Summary

M.S.Q. Ventures announced that its client, BioLineRx (NASDAQ/TASE: BLRX), has entered into a co-development agreement with GenFleet Therapeutics for the cancer treatment Motixafortide in pancreatic ductal adenocarcinoma (PDAC). The agreement involves a Phase 2b clinical trial in China with around 200 patients, aiming to assess the efficacy of Motixafortide combined with anti-PD-1 and chemotherapy. Results from the preceding Phase 2a study suggest potential benefits, and this collaboration is expected to expedite PDAC treatment development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
none
-
Rhea-AI Summary

BioLineRx (NASDAQ: BLRX) has entered a collaboration with GenFleet Therapeutics to conduct a Phase 2b trial of Motixafortide for first-line metastatic pancreatic cancer (PDAC) in China. GenFleet will fund and execute the trial, evaluating Motixafortide combined with anti-PD-1 and chemotherapy against standard chemotherapy. This partnership follows positive results from the Phase 2a COMBAT/KEYNOTE-202 study, which showed improved outcomes in second-line PDAC therapy. BioLineRx retains global rights to Motixafortide and plans to submit a New Drug Application for stem cell mobilization soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) has appointed Holly W. May as its Chief Commercial Officer, a newly established role, effective June 16, 2022. Ms. May brings extensive experience in commercial strategy, having led 13 product launches, and will focus on the U.S. market for Motixafortide, pending FDA approval. The U.S. market for Motixafortide in stem cell mobilization is projected to be worth $360 million annually. BioLineRx aims to submit a New Drug Application to the FDA in mid-2022, continuing preparations for Motixafortide's launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
management

FAQ

What is the current stock price of BioLineRX (BLRX)?

The current stock price of BioLineRX (BLRX) is $3.57 as of January 30, 2025.

What is the market cap of BioLineRX (BLRX)?

The market cap of BioLineRX (BLRX) is approximately 528.1M.

What does BioLineRx Ltd. specialize in?

BioLineRx Ltd. specializes in developing therapies for oncology and rare diseases.

What is APHEXDA®?

APHEXDA® (motixafortide) is a stem cell mobilization agent for autologous transplantation in multiple myeloma patients.

What are some of BioLineRx's key therapeutic candidates?

Key therapeutic candidates include motixafortide (BL-8040) and AGI-134, aimed at treating solid tumors and supporting stem cell mobilization.

Where is BioLineRx Ltd. headquartered?

BioLineRx Ltd. is headquartered in Modi'in, Israel.

Who are BioLineRx's collaboration partners for gene therapy?

BioLineRx collaborates with St. Jude Children's Research Hospital and Washington University School of Medicine for gene therapy.

What recent financial actions has BioLineRx taken?

BioLineRx announced the issuance and sale of ADSs and warrants, along with utilizing an existing debt facility for financial resources.

What was discussed at the recent conferences BioLineRx attended?

BioLineRx presented new data on motixafortide and its applications in oncology at the ASCO and ISPOR conferences.

What is AGI-134?

AGI-134 is an immuno-oncology agent in development for treating solid tumors.

Can I invest in BioLineRx Ltd.?

Yes, BioLineRx Ltd. is publicly traded on NASDAQ under the symbol BLRX.

Where can I find more information about BioLineRx?

To learn more about BioLineRx, visit their official website at www.biolinerx.com and follow them on Twitter and LinkedIn.
BioLineRX Ltd

Nasdaq:BLRX

BLRX Rankings

BLRX Stock Data

528.05M
135.51M
8.54%
3.09%
1.33%
Biotechnology
Healthcare
Link
United States of America
Hevel Modi'in